---
title: Hemostemix Investor Information | Clinical-Stage Biotech
description: Investor information for Hemostemix Inc., a clinical-stage regenerative medicine company advancing ACP-01 for vascular and ischemic disease.
---
[](https://hemostemix.com?hsLang=en)
[Latest News](https://hemostemix.com/latest-news?hsLang=en)
INVESTMENT CASE
# Restoring blood flow and quality of life. Restoring human potential.
Hemostemix is advancing ACP-01, an investigational autologous angiogenic cell therapy derived from a patient's own blood, supported by two decades of human clinical research across cardiovascular, peripheral vascular and neurological ischemic disease.
---
20+
years of clinical development
498
patients including 7 completed studies (318 subjects)
11
peer-reviewed publications
Multiple
ischemic indications
[Investor 2-Pager](https://investors.hemostemix.com/hubfs/2026%202%20Pager.pdf?hsLang=en)
[Request a Family Office Briefing](https://hemostemix.com/thomas-smeenk?hsLang=en)
[Enter the Due Diligence Data Room](https://hemostemix.com/thomas-smeenk?hsLang=en)
TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0
**WHY NOW**
Two decades of science. A defined commercial inflection ahead.
Each milestone changes the company's risk profile. Regulatory decision de-risks market access. First patient converts a filing into an operating program. First 20 enrolled proves the funnel.
COMPLETED
- Prior Phase I and Phase II clinical work
---
- Peer-reviewed cardiac and CLTI publications
---
- Manufacturing technology and IP
---
- FDA regulatory engagement
---
- Bahamas commercial application filed Completed · Jul 8, 2026
---
- Bahamas regulatory Received October 7, 2026
---
- Manufacturing partner selected
---
NEXT 5 TO 12 MONTHS
- First commercial Phase I patient Planned · Q2 2027
---
- Angina study commencement Planned · Q2 2027
---
- Manufacturing batches released Planned · Q2 2027
---
- First 20 patients enrolled Planned · Q2 2027
---
- Real-world evidence database activated Planned
---
---
CLINICAL EVIDENCE
## The most published cell therapy in its class.
Seven completed clinical studies. Eleven peer-reviewed publications. Follow-up extending to 4.5 years. Each study links directly to its publication.
Study & indication
Design & patients
Plain language improvement
Source
Studies:
Mutirangura 2009
CLTI
Open-label pilot; 6 no-option patients; intramuscular
83.3% meaningful improvement in circulation; 66.7% complete wound or stump healing.
[Link](https://pubmed.ncbi.nlm.nih.gov/19301723/)
---
Tresukosol 2006
Refractory angina
Phase I open-label; 24 patients; intracoronary
Walked 24.4% farther in 6 min. Angina severity down 50%. Perfusion defect down ~45%.
[Link](https://www.ahajournals.org/doi/10.1161/circ.114.suppl_18.II_786-c)
---
Szabó 2013
PAD/CLTI
Phase II randomized; 13 treated / 8 control
3-month amputations 0% vs 60%. At 2 years, 70% vs 40% amputation-free.
[Link](https://pubmed.ncbi.nlm.nih.gov/23993298/)
---
Arom 2008
Cardiomyopathy
Open-label; 41 patients; intramyocardial
Pumping function +18% overall, +26.3% ischemic. Walking distance +36.7%
[Link](https://investors.hemostemix.com/hubfs/Asian-Annals.pdf?hsLang=en)
---
Chaithiraphan 2009
Ischemic CM & angina
Open-label; 106 patients; transcoronary
Angina severity down ~41.8%. Symptom severity down ~39%.
[Link](https://pubmed.ncbi.nlm.nih.gov/23993298/)
---
Schubart/Henderson 2023
Cardiomyopathy
Retrospective; 53 patients; intracoronary
Most severe subgroup nearly doubled pumping function (~94.5% relative).
[Link](https://link.springer.com/article/10.1186/s13287-023-03539-6)
---
Henderson et al. 2024
Wound / Ulcer Healing
Phase II randomized; 21 treated / 8 control
Wound size down ~72.6% at 3 months. Event-rate differences not statistically significant.
[Link](https://link.springer.com/article/10.1186/s13287-023-03539-6)
---
Published investigational findings. ACP-01 has not received FDA or Health Canada marketing approval. Individual outcomes in future studies may vary.
PATIENT IMPACT
## The evidence has a human shape. It started with our founder.
Shared with each patient's consent. Every account is one person's experience, bounded and attributed. The science carries the case. These are why the case is being made.
Roger Bergersen
Founder & patient
Received an early version of ACP-01 in 2005 for critical heart disease. Credited it with saving his life and founded the company. Lived 15 more years.
---
Howie Lindeman
Ischemic cardiomyopathy
Chose ACP-01 over open-heart surgery in 2008 as one of the first ~50 patients. In his account, returned to a decade of touring and active diving. Now in his 70s.
---
Niem Malo
Post-infarction, EF 28%
Told he had a year to live at 47. In his account, ejection fraction improved from 28% toward near-normal, his defibrillator was switched off, and 16+ years on he still runs his restaurant.
---
Each account is the patient's own, published with consent. Individual outcomes vary and do not predict results for any other patient. ACP-01 is investigational.
COMMERCIALIZATION & REVENUE MODEL
A defined operating model, separated from the science.
Patient inquiry
Physician screening
Blood collection
cGMP maunfacturing
Hospital Adminstration
Follow-up + RWE + revenue
---
REGULATORY ROADMAP
## A jurisdictional strategy, stated plainly.
Jurisdiction
Current status
Permitted activity
Next milestone
The Bahamas
LARTA application approved; commercial Phase I
Activities permitted following final approval
Final approval and first treatment
---
Florida
Limited state framework (SB 1768)
Wound care and pain management within physician scope
Counsel-confirmed compliant program
---
Canada
Investigational product
Special-access pathways as applicable
First Nations joint venture
---
Puerto Rico
Manufacturing and R&D structure
Manufacturing subject to applicable federal rules
Facility qualification
---
Hemostemix does not characterize any FDA discussion or feedback as approval or acceptance. The FDA recognizes that real-world evidence can contribute to regulatory decision-making, subject to data quality, study design and the specific regulatory question. LARTA authorization is a sovereign Bahamian framework and does not constitute FDA or Health Canada approval.
Manufacturing & Intellectual Property
## Built to scale, protected by IP.
95
Patents protecting the platform
7 days
Blood draw to release
cGMP process.
2
Facilities modeled
20 to 40 treatments each per month.
---
LEADERSHIP & GOVERNANCE
## The people and the governance behind the platform.
###### Thomas Smeenk
Director, CEO, Co-Founder
A chief executive who structures, negotiates and has closed eight figure contracts. A dynamic business development and management team leader who delivers timely profitable results domestically and internationally. An adept communicator who succeeds at collaborative and interpersonal relationships with management, prospects, clients and suppliers.
###### Peter Lacey
Chairman
Chairman of Cervus Equipment Corporation (CERV.TO), from inception to date.
President and Chief Executive Officer of Cervus Equipment Corporation and its predecessor entities from 1982 to April 2012.
Cervus is a company he and his partners started in 1999 and built from five John Deere dealerships to 63 dealerships selling six brands in three countries with revenues of $1.1 Billion.
Graduate of the Institute of Corporate Directors Education Program at the University of Toronto.
###### Dr. Ronnie Hershman
Director
Graduated Magna Cum Laude from Sophie Davis Center for Biomedical Research in 1980.
Practicing Cardiologist since 1987 and Medical Director of NYU Langone Long island Cardiac Care.
Pioneer in performing laser assisted coronary angioplasty.
Entrepreneur and investor for more than two decades and director and/or officer of over 9 life science companies.
Track record of investing in companies that commercialize technologies quickly and globally.
Advisor to late stage life science VC that has funded 24 companies.
###### Loran Swanberg
Director
Part owner and a director of a private company, Landsman Properties Ltd. since 2005. Landsman owns and leases out shop and office space in North East British Columbia and Alberta.
From 1992 to 2005, Mr. Swanberg was a director of the family owned oilfield transportation company, Swanberg Bros. Trucking Ltd., which was purchased by Producers Oilfield Services Inc. in 2005.
Director of privately held Swanberg Air Inc. from 2000 to 2012, and was a director of the Northern B.C. Truckers’ Association for 10 years, 1992 to 2002.
Most recently, Mr. Swanberg was a partner and director of Vieworx Geophoto Inc. from 2012 until Q1 2020.
###### Dr. Desirée Cox
Director
Dr. Desirée Cox (MD, MPhil, PhD) is a physician, scientist, bioethicist, and Rhodes Scholar whose work spans medicine, ethics, public policy, and regenerative medicine with degrees from McGill University (BSc), Oxford (MD, as a Rhodes Scholar), and Cambridge (MPhil, PhD).
For more than a decade, Dr. Cox has led regenerative medicine ethics and governance in The Bahamas, chairing the National Stem Cell Ethics Committee and helping build the legislative framework behind the country's Longevity and Regenerative Therapies Act (LARTA) — positioning The Bahamas as a hub for responsible longevity science. She is the founder of HEALinc, a global health innovation platform working to make regenerative, longevity-enhancing technologies more accessible.
## FINANCIALS
## Easy to find, complete.
Here are the quarterly and annual Financials Statements and Management Discussion & Analysis together in one file for each year. Additionally, a link to the company profile on Sedar+ is included..
[2026 Documents (to date)](https://investors.hemostemix.com/hubfs/2026_Hemostemix_TO_DATE_Financials_%26_MD%26A.zip?hsLang=en)
[2025 Documents](https://investors.hemostemix.com/hubfs/2025_Hemostemix_Financials_%26_MD%26A.zip?hsLang=en)
[2024 Documents](https://investors.hemostemix.com/hubfs/2024_Hemostemix_Financials_%26_MD%26A.zip?hsLang=en)
[2023 Documents](https://investors.hemostemix.com/hubfs/2023_Hemostemix_Financials_%26_MD%26A.zip?hsLang=en)
[Hemostemix on Sedar+](https://www.sedarplus.ca/csa-party/records/profile.html?id=ca49a7148a98de1c311c77e0a97c2c96)
FAMILY OFFICE DATA ROOM
## Where interest becomes diligence.
🔒
NDA-controlled, password protected
The public site creates interest. The data room converts interest into diligence. Access requires NDA execution and credential issue.
[Request Access](https://hemostemix.com/thomas-smeenk?hsLang=en)
[2-page investment summary](https://hemostemix.com/thomas-smeenk?hsLang=en)
[Investor Deck](https://hemostemix.com/thomas-smeenk?hsLang=en)
[Cap Table](https://hemostemix.com/thomas-smeenk?hsLang=en)
[Financial Model](https://hemostemix.com/thomas-smeenk?hsLang=en)
[Historical Financials](https://hemostemix.com/thomas-smeenk?hsLang=en)
[Clinical Study Summaries](https://hemostemix.com/thomas-smeenk?hsLang=en)
[Clinical Protocols](https://hemostemix.com/thomas-smeenk?hsLang=en)
[Manufacturing Agreements](https://hemostemix.com/thomas-smeenk?hsLang=en)
WHY FAMILY OFFICES INVEST
## Purpose, return and protection.
###### Purpose
Capital supports a patient-derived therapy intended to restore blood flow, mobility, independence and meaningful family life. Buy two TCDs and donate one, invest in the equity, or invest in the SPV.
###### Return
Large patient populations, a defined price per treatment, a modeled contribution margin, scalable manufacturing, clinic-level economics and the regulatory value of the resulting real-world evidence.
###### Protection
Insider capital per SEDI, management equity ownership, milestone-based deployment, quarterly reporting, independent governance, secured manufacturing, scenario-based dilution and clearly stated risks.
[Request a Family Office Briefing](https://hemostemix.com/thomas-smeenk?hsLang=en)
IMPORTANT NOTICE
ACP-01 is an investigational therapy and has not been approved by the U.S. Food and Drug Administration or Health Canada. Information provided on this website is for educational purposes only and does not constitute medical advice. Patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions.
FORWARD-LOOKING STATEMENTS
This website contains forward-looking statements regarding clinical, regulatory, manufacturing and commercial plans. These reflect current expectations and are subject to risk and uncertainty. Actual results may differ materially. Investors should review all public disclosures on SEDAR+ before making investment decisions.
FLORIDA NOTICE
This notice is provided in accordance with Florida law. One or more physicians referenced may perform stem cell therapies that have not been approved by the United States Food and Drug Administration. Patients are encouraged to consult with their primary care provider before undergoing any stem cell therapy.
[](https://hemostemix.com/?hsLang=en)
Contact Us